High-Risk Pulmonary Embolism: Current Evidence-Based Practices

Area of Science:

• Cardiology
• Pulmonology
• Vascular Medicine

Background:

• Acute pulmonary embolism (PE) is a leading cause of morbidity and mortality.
• Right ventricular (RV) dysfunction is a critical factor in PE prognosis.
• Accurate risk stratification is essential for guiding PE treatment decisions.

Purpose of the Study:

• To review the current understanding of risk stratification in acute pulmonary embolism.
• To discuss the role and controversies surrounding reperfusion therapies in intermediate and high-risk PE.
• To highlight the need for further research into advanced reperfusion strategies.

Main Methods:

• Literature review of current guidelines and studies on PE management.
• Analysis of risk stratification tools focusing on RV function.
• Evaluation of different reperfusion strategies: systemic thrombolysis, catheter-directed thrombolysis (CDT), and embolectomy.

Main Results:

• High-risk PE patients generally benefit from reperfusion therapy, primarily systemic thrombolysis.
• The use of reperfusion therapies in intermediate-risk PE remains controversial.
• Catheter-directed thrombolysis (CDT) may be considered for select intermediate-risk patients, but lacks robust comparative data.
• Surgical or catheter embolectomy are alternatives for high-risk patients with contraindications to thrombolysis.

Conclusions:

• Risk stratification, particularly RV function assessment, is crucial for managing acute PE.
• Systemic thrombolysis is recommended for high-risk PE.
• Further research is needed to define the optimal use of advanced reperfusion therapies, including CDT, in intermediate-risk PE patients.